Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat + Pembrolizumab + Chemotherapy in Advanced Solid Tumors
NCT03085914Phase 2Completed
- Sponsor
- Incyte
- Start
- May 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of epacadostat in solid tumor (7 arms), sponsored by Incyte. Primary endpoints: Treatment-emergent Adverse Events up to 21 months, Dose Limiting Toxicities at 28 days and 1 more. Started May 2017; status: completed.
02
Drugs
epacadostat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03085914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085914.